文献速递糖尿病

内源性GIP参与2型糖尿病患者餐后内脏血供调节:随机单盲安慰剂对照交叉研究

GIP contributes to postprandial regulation of splanchnic blood supply in humans with type 2 diabetes: a randomised, single-blinded, placebo-controlled, crossover study.
PubMed 文献 · Diabetologia · 2026-07-02

结果显示口服葡萄糖使肠系膜上动脉平均血流量增加57%(95%CI 26,88),合并GIP受体拮抗剂输注时该增幅降低15%(95%CI -2,32),p=0.012;GIP受体拮抗剂还降低胰岛素分泌和C肽,但不影响胰高血糖素和血糖。结论提示内源性GIP参与2型糖尿病患者餐后内脏血流增加。

要点

  • 在2型糖尿病患者中,口服葡萄糖使肠系膜上动脉血流量增加57%。
  • GIP受体拮抗剂使葡萄糖诱导的肠系膜上动脉血流增幅降低15%(p=0.012)。
  • GIP受体拮抗剂降低胰岛素分泌和C肽,但不影响胰高血糖素和血糖。

核心结论

  • 内源性GIP参与2型糖尿病患者餐后内脏血流量增加。

研究设计与样本

  • 受试者在四次独立 occasions 分别接受口服葡萄糖+静脉GIP(3-30)NH2、口服葡萄糖+静脉生理盐水(154 mmol/l NaCl)、口服水+静脉GIP(3-30)NH2、口服水+静脉生理盐水。
  • 采用相位对比MRI测量肠系膜上动脉、腹腔干和门静脉的血流,口服葡萄糖剂量为75 g。
  • 研究在哥本哈根Rigshospitalet进行,随机化使用random.org,受试者不知分组而研究者知晓。

主要发现

  • 单纯口服葡萄糖使肠系膜上动脉平均血流量增加57%(95%CI 26, 88)。
  • 合并GIP受体拮抗剂输注时,肠系膜上动脉血流增幅较单纯口服葡萄糖降低15%(95%CI -2, 32),p=0.012。
  • 口服葡萄糖期间输注GIP受体拮抗剂较输注生理盐水降低胰岛素分泌、C肽及C肽/葡萄糖比值,而胰高血糖素水平和血浆葡萄糖不受影响。
  • 口服水对任何结局均无影响。

关键数值与推荐

  • 主要结局为口服葡萄糖伴或不伴GIP受体拮抗剂输注期间肠系膜上动脉血流变化。
  • 口服葡萄糖使肠系膜上动脉平均血流量增加57%(95%CI 26, 88);GIP受体拮抗剂使其降低15%(95%CI -2, 32),p=0.012。

临床怎么用

  • 对于2型糖尿病患者,内源性GIP在餐后内脏血流调节中具有作用,GIP受体拮抗可减弱餐后肠系膜上动脉血流增加并降低胰岛素分泌。
  • GIP受体拮抗不影响胰高血糖素和血糖,提示其血管效应与胰岛素分泌变化可能独立于血糖调控。

局限性

  • 研究为单盲设计,仅受试者不知分组而研究者知晓。
  • 未采用额外的分配隐藏程序。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: In healthy lean humans, endogenous glucose-dependent insulinotropic polypeptide (GIP) contributes significantly to the postprandial increase in arteria mesenterica superior blood flow. The vascular biology related to activation of the GIP receptor is markedly impaired in individuals with type 2 diabetes and is sometimes absent. In this population, we investigated the role of endogenous GIP on postprandial splanchnic blood flow by using the GIP receptor antagonist, GIP(3-30)NH2. The primary outcome of this study was the changes in blood flow in arteria mesenterica superior during oral glucose with or without GIP receptor antagonist infusion. METHODS: Ten participants with type 2 diabetes (age 20-80 years, BMI 20-35 kg/m2, and HbA1c >48 mmol/mol and <75 mmol/mol) were investigated in a randomised, placebo-controlled, crossover study. On four separate occasions, participants received the following treatment: oral glucose + i.v. GIP(3-30)NH2; oral glucose + i.v. saline (154 mmol/l NaCl); oral water + i.v. GIP(3-30)NH2; oral water + i.v. saline. Participants were randomly assigned to intervention groups using (random.org). Participants were unaware of allocation, while investigators were aware. No additional allocation concealment procedures were used. During all four interventions, splanchnic blood flow was measured using phase-contrast MRI in the arteria mesenterica superior, truncus coeliacus and vena portae during oral glucose (75 g) or water ingestion. The study was conducted at Rigshospitalet, Copenhagen. Liver volume and oxygenation, as well as gallbladder volume, were assessed. Blood samples were collected and analysed for insulin, C-peptide, GIP, glucagon and glucose. RESULTS: Oral glucose alone increased mean blood flow in arteria mesenterica superior by 57% (95% CI 26, 88) and this was 15% (95% CI -2, 32) lower during concomitant GIP receptor antagonist infusion, p=0.012. Infusion of GIP receptor antagonist during oral glucose treatment did also result in lower insulin secretion, C-peptide and C-peptide/glucose ratio compared with saline infusion, whereas glucagon levels and plasma glucose were unaffected. Oral water did not affect any outcomes. CONCLUSIONS/INTERPRETATION: Endogenous GIP contributes to postprandially increased splanchnic blood flow in people with type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT06426823 FUNDING: This work was supported by the Novo Nordisk Foundation.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Rasmussen RS, Nielsen SW, Alstrup L, et al. GIP contributes to postprandial regulation of splanchnic blood supply in humans with type 2 diabetes: a randomised, single-blinded, placebo-controlled, crossover study. Diabetologia. 2026. PMID: 42393405. doi:10.1007/s00125-026-06788-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。